Skip to content
NOWCAST KCRA 3 News at 7pm
Live Now
Advertisement

Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds

Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds
THERE HAS BEEN A FRENZY, OF COURSE, OVER DRUGS THAT HAVE SHOWN DRAMATIC SUCCESS HELPING PEOPLE LOSE WEIGHT. BUT HOW IS THAT DEMAND IMPACTING OUR KIDS HERE WITH SOME INSIGHT, AS DOCTOR SCOTT HADLAND, CHIEF OF YOUNG ADULT MEDICINE AT MASS GENERAL FOR CHILDREN, GREAT TO SEE YOU, DOCTOR HADLAND. GOOD. GOOD TO SEE YOU TOO. THANKS FOR COMING IN. ALL RIGHT. SO IT SEEMS LIKE THESE ADS, THEY ARE EVERYWHERE. DRUGS LIKE OZEMPIC WEGOVY. WHAT KINDS OF CONVERSATIONS ARE YOU HAVING WITH KIDS AND PARENTS ABOUT THIS TREND? LOTS OF CONVERSATIONS. THESE MEDICATIONS ARE CALLED GLP ONE AGONISTS. THEY’VE BEEN AROUND FOR QUITE SOME TIME FOR TREATMENT OF DIABETES, BUT ONLY MORE RECENTLY HAVE BEEN USED TO TREAT KIDS WHO WHO HAVE SORT OF EXCESS WEIGHT OR MIGHT MEET CERTAIN CRITERIA. AND THE MAIN MEDICATION THAT’S APPROVED FOR KIDS 12 AND UP IS WEGOVY. AND WEGOVY IS A MEDICATION THAT I GET SO MANY QUESTIONS ABOUT. AND SO WHAT FAMILIES WANT TO KNOW IS, IS THIS MEDICATION APPROPRIATE FOR MY CHILD? AND IT’S A REALLY AN INDIVIDUALIZED CONVERSATION THAT WE NEED TO HAVE BECAUSE THERE ARE LOTS OF DIFFERENT OPTIONS, RIGHT. THIS IS ONE TOOL IN OUR TOOL BELT. WE ALSO KNOW THAT WEIGHT LOSS APPROACHES, INCLUDING LIKE DIET AND EXERCISE, CAN BE REALLY EFFECTIVE. THERE ARE OTHER MEDICATIONS AVAILABLE TOO, SO WE’RE HAVING LOTS OF RICH CONVERSATIONS ABOUT WHAT IS THE RIGHT APPROACH FOR A CHILD WHO MIGHT BE STRUGGLING. WELL. AND WE ALL KNOW IN TEEN YEARS, BODY IMAGE CAN BE CRITICAL. AND OF COURSE, MAYBE SOME TEENS, YOU KNOW, OBESITY IS A HEALTH ISSUE, BUT OTHERS, YOU KNOW, MAYBE IT ISN’T. SO HOW DO YOU KIND OF NAVIGATE THOSE DIFFICULT WATERS? YEAH, I THINK THE MOST IMPORTANT THING FOR US TO DO IS REALLY FOCUS ON HEALTH RATHER THAN WEIGHT. AND SO, YOU KNOW, I THINK WE IN THE MEDICAL PROFESSION HAVE BEEN GUILTY FOR A LONG TIME OF FOCUSING ON NUMBERS, FOCUSING ON SOMEBODY’S WEIGHT, ON THEIR BODY MASS INDEX OR BMI. BUT WHAT WE REALLY NEED TO BE DOING IS FOCUSING, FOCUSING ON SOMEBODY’S HEALTH AND THEIR WELL-BEING AND HOW THEY’RE FEELING. AND, YOU KNOW, THERE ARE LOTS OF KIDS WITH ABOVE AVERAGE WEIGHTS WHO ARE VERY HAPPY AND HEALTHY. AND SO BECAUSE THEY HAVE GREAT WELL-BEING, WE DON’T NEED TO MAKE A CHANGE. THERE. BUT, YOU KNOW, ON THE OTHER END OF THE SPECTRUM, THERE ARE SOME KIDS WHO ARE UNDERWEIGHT AND THAT CAN BE UNHEALTHY TOO. AND SO WHEN WE FOCUS ON HEALTH AND WHEN WE FOCUS ON WELL-BEING RATHER THAN NUMBERS, THAT’S REALLY WHERE WE’RE HITTING THE SWEET SPOT. I WANT TO ASK YOU SOMETHING ABOUT THESE MEDICATIONS. SO YOU SAY WEGOVY IS APPROVED FOR 12 AND UP. BUT THESE ADS KIND OF INDICATE THAT ONCE YOU GO ON IT, YOU GOT TO STAY ON IT. IS THAT THE CASE TOO? LIKE IF YOU GO ON A MEDICATION AT 12, 13, 14, YOU HAVE TO STAY ON IT FOR THE REST OF YOUR LIFE. YEAH, I THINK THAT’S WHY WE NEED TO BE HAVING THESE CAREFUL CONVERSATIONS, BECAUSE, YOU KNOW, WEGOVY IS A ONCE WEEKLY INJECTION, WHICH IS NOT EASY FOR ALL KIDS TO DO, RIGHT? WE KNOW KIDS DON’T NECESSARILY LIKE NEEDLES, AND THIS IS A MEDICATION THAT STUDIES HAVE SHOWN IF YOU STOP TAKING IT, MOST PEOPLE WILL REGAIN MOST OF THE WEIGHT THAT THEY LOST. AND SO AT THIS POINT, WE ARE SORT OF TREATING THESE AS MEDICATIONS THAT PEOPLE NEED TO BE ON IN THE LONG TERM. SO WE NEED TO HAVE THAT CONVERSATION UP FRONT BEFORE WE START THE MEDICATION. OKAY. IMPORTANT
Advertisement
Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds
GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests.People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer a person is overweight and the more excess weight they gain. About 40% of new cancer diagnoses are associated with excess weight, according to the U.S. Centers for Disease Control and Prevention. In 2021, there were about 170 new diagnoses for every 100,000 people, CDC data shows.But a study published Friday in the journal JAMA Network Open found that people with type 2 diabetes who were being treated with a class of GLP-1 drugs were significantly less likely to be diagnosed with 10 of the 13 obesity-associated cancers than those who were taking insulin.The risk was cut by more than half for gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma, a kind of liver cancer. It was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer.Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer, according to the CDC. And GLP-1 medications interact with systems related to insulin production.The new findings that link GLP-1 treatment to reduced risk of some cancers "compare favorably" with similar effects linked to intensive lifestyle intervention and metabolic-bariatric surgery that have been found in other trials, the study authors wrote.However, the research found that GLP-1 treatment was not associated with a reduced risk of postmenopausal breast cancer, which CDC data shows is the most common type of cancer associated with obesity.Risk was also not reduced for stomach cancer or thyroid cancer. In fact, other research has found that GLP-1s may interact with the body's insulin production in ways that negatively affect the thyroid, and the study authors note that patients should be aware of potential thyroid-related risks that are included on the medication's packaging.The new study also found that the risk of cancer diagnosis for people with type 2 diabetes was not different among those who were treated with GLP-1s compared with those where were being treated with metformin. In fact, the risk of diagnosis with kidney cancer was higher among those using GLP-1s than those on metformin.For this study, researchers from the Case Western Reserve University School of Medicine and the MetroHealth System analyzed more than a decade of medical records for nearly 1.7 million people with type 2 diabetes.More information is needed about how reduced cancer risk may relate to the scale of weight loss, but the findings provide "preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies," the study authors wrote.

GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests.

People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer a person is overweight and the more excess weight they gain. About 40% of new cancer diagnoses are associated with excess weight, according to the U.S. Centers for Disease Control and Prevention. In 2021, there were about 170 new diagnoses for every 100,000 people, CDC data shows.

Advertisement

But a study published Friday in the journal JAMA Network Open found that people with type 2 diabetes who were being treated with a class of GLP-1 drugs were significantly less likely to be diagnosed with 10 of the 13 obesity-associated cancers than those who were taking insulin.

The risk was cut by more than half for gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma, a kind of liver cancer. It was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer.

Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer, according to the CDC. And GLP-1 medications interact with systems related to insulin production.

The new findings that link GLP-1 treatment to reduced risk of some cancers "compare favorably" with similar effects linked to intensive lifestyle intervention and metabolic-bariatric surgery that have been found in other trials, the study authors wrote.

However, the research found that GLP-1 treatment was not associated with a reduced risk of postmenopausal breast cancer, which CDC data shows is the most common type of cancer associated with obesity.

Risk was also not reduced for stomach cancer or thyroid cancer. In fact, other research has found that GLP-1s may interact with the body's insulin production in ways that negatively affect the thyroid, and the study authors note that patients should be aware of potential thyroid-related risks that are included on the medication's packaging.

The new study also found that the risk of cancer diagnosis for people with type 2 diabetes was not different among those who were treated with GLP-1s compared with those where were being treated with metformin. In fact, the risk of diagnosis with kidney cancer was higher among those using GLP-1s than those on metformin.

For this study, researchers from the Case Western Reserve University School of Medicine and the MetroHealth System analyzed more than a decade of medical records for nearly 1.7 million people with type 2 diabetes.

More information is needed about how reduced cancer risk may relate to the scale of weight loss, but the findings provide "preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies," the study authors wrote.